Phase 3 Readout

ABUS: Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy

Name: Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy
Start: 2030-08-15
End: 2030-08-15

August 15, 2030 · eribulin. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 15, 2030
Company: Arbutus Biopharma Corp (ABUS)
Drug: eribulin

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy

August 15, 2030

ABUS overview →

Company: Arbutus Biopharma Corp (ABUS)
Drug: eribulin
Indication: Metastatic Bladder Urothelial Carcinoma; Stage IV Bladder Cancer AJCC v8; Metastatic Urothelial Carcinoma